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Summary
Prescribing data for Europe show a shift from inhaled corticosteroids (ICSs) prescribed
alone or in free combination with long-acting b2-agonists (LABAs) to ﬁxed-dose single-inhaler
combinations of these agents. However, existing guidelines provide little advice on selecting
a speciﬁc ICS/LABA combination therapy for the treatment of asthma. European survey data
indicate that the factors physicians take into account when making prescribing decisions
are broadly in line with those considered to be important by experts in a Delphi process:
the availability of a range of doses, the efﬁcacy of the combination, the long-term safety
and tolerability of the ICS and LABA components, the potency of the ICS and the speed of
onset of the LABA. Further research is needed to help inform physician choice of ICS/LABA
combinations for patients with asthma.
© 2012 Elsevier Ltd. All rights reserved.
Introduction
The combination of an inhaled corticosteroid (ICS) and
a long-acting b2-agonist (LABA) is recommended by most
guidelines, including those from the Global Initiative for
Asthma,1 as a treatment option for patients whose asthma
is not controlled by a low-dose ICS alone.2,3 Several ICSs
and LABAs are licensed for use as asthma therapy and
four ICS/LABA combinations are available as ﬁxed-dose
treatments. Guidelines provide little advice on selecting
a speciﬁc ICS/LABA combination for the treatment of
asthma,1 reﬂecting the lack of conclusive evidence to
differentiate between available therapies.4,5
In the absence of clear guidance, it is uncertain how
physicians select the ICS/LABA therapy that is most
appropriate for a particular patient. The aim of this article
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is to provide insight into physician choice of ICS/LABA
combinations, with a particular focus on a review of
recent attitudinal studies that evaluated the real-world
perceptions underlying these prescribing decisions.
Prescribing trends: which treatments do
physicians choose?
A recent European study obtained information on the
retail prescribing of ICSs (alone and in free or ﬁxed-
dose combination with LABAs) in 12 European countries
(Austria, Denmark, Finland, France, Germany, Ireland, Italy,
the Netherlands, Spain, Sweden, Switzerland and the UK)
between October 2004 and September 2009.6 Data were
collated from the MIDAS database (IMS Health, London,
UK), a multinational database of sales information from
wholesalers, hospitals and pharmacies in over 70 countries.
Analysis of these sales data showed that the pre-
scription of ICSs in ﬁxed-dose combinations increased by
almost 50% over the 5-year study period, whereas the
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Figure 1. Retail prescribing of inhaled corticosteroids (ICSs)
alone or in free combination and in ﬁxed combination with long-
acting b2-agonists (LABAs) for the treatment of patients with
asthma in Europe, 2005 2009.6
prescription of ICSs as monotherapy (or in free combination)
decreased slightly (Fig. 1).6 Beclometasone dipropionate
(beclometasone) was the most commonly prescribed ICS
monotherapy, accounting for 54% of ICS inhalers prescribed
in the ﬁnal year of the study; budesonide and ﬂutica-
sone propionate (ﬂuticasone) comprised 30% and 16% of
monotherapy prescriptions, respectively.6 In contrast, data
for ICSs prescribed as an ICS/LABA ﬁxed-dose combination
demonstrated that ﬂuticasone was the most widely pre-
scribed ICS in the ﬁnal year of the study (59% of all ﬁxed-
dose combination inhalers prescribed). Budesonide was the
second most commonly prescribed ICS (within a ﬁxed-dose
combination), accounting for 35% of inhaler sales, and
beclometasone (this drug has only been available in a ﬁxed-
dose combination since 2008, despite being the oldest ICS
monotherapy for asthma) was the least often prescribed
ICS, accounting for just 6% of ICS/LABA inhaler sales (Fig. 2;
unpublished data).
When prescription data were pooled for both ICS
monotherapies and ICSs available within ICS/LABA ﬁxed-
dose combinations, they showed that ﬂuticasone was the
most widely prescribed ICS overall (accounting for 38% of all
inhalers prescribed in the ﬁnal year of the study), followed
by budesonide (33%) and beclometasone (29%).6
Insight into LABA prescribing trends was gained from anal-
ysis of recent data capturing new LABA prescriptions for the
treatment of respiratory disease, from January to December
2011 in France, Germany, Italy, Spain and the UK (Cegedim
Strategic Data, Surrey, UK). New prescriptions were deﬁned
as those issued to patients who had not received an inhaled
LABA prescription in the previous 12 months; patients who
were prescribed a LABA or ﬁxed-dose combination therapy
as a replacement for an existing therapy; and patients
for whom a LABA was added to their continued, original
therapy. Overall, there were more than 7.44 million new
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Figure 2. Retail prescribing of inhaled corticosteroids in ﬁxed-
dose combination with long-acting b2-agonists for the treatment
of patients with asthma in Europe, 2005 2009.
prescriptions for LABAs during 2011 in these ﬁve countries,
with formoterol accounting for 55% of these prescriptions,
compared with 40% for salmeterol and 5% for indacaterol.7
A long-term study of the sales of inhalers from retail
pharmacies in France, Germany, Italy, Spain and the UK for
the period from Q4 2005 to Q4 2011 provides an overview
of trends in device use for the treatment of respiratory
disease (MIDAS database; IMS Health, London, UK). Overall,
pressurized metered-dose inhalers (pMDIs) accounted for
more than half of the total inhalers used in every
quarter analysed, compared with use of reﬁllable and non-
reﬁllable dry-powder inhalers (DPIs) or breath-actuated
metered-dose inhalers (BA-MDIs). In the most recent quarter
analysed, pMDIs accounted for 56% of inhalers used,
compared with 26% for non-reﬁllable DPIs, 15% for reﬁllable
DPIs and 3% for BA-MDIs.8
Prescriber attitudes: how do physicians
choose an ICS/LABA combination?
Two recent attitudinal surveys explored physician attitudes
and perceptions toward combinations of ICSs and LABAs
for the ﬁxed-dose combination treatment of patients
with asthma.9,10 In the ﬁrst of these studies (performed
in November 2009), a group of respiratory specialists
practising in the UK completed a structured online survey to
evaluate the perceived effectiveness of different ICS/LABA
combinations.9 The group of physicians was recruited
via medeConnect Healthcare Insight (Abingdon, UK) from
www.doctors.net.uk, which is the largest professional
network of physicians in the UK. Survey respondents (n = 82)
were asked to consider which combination of an ICS and
a LABA they would perceive to be most effective for the
treatment of asthma (whether or not the combination
was commercially available as a ﬁxed-dose therapy at
the time of the survey). The most effective combination
was considered to be ﬂuticasone/formoterol (41% of the
respondents, prompted answers), followed by budesonide/
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Table 1
Inhaled corticosteroid (ICS)/long-acting b2-agonist (LABA) combinations most preferred by practising physicians in
13 European countries (n = 1007) for treating patients with asthma
ICS/LABA combination Physicians with preference Countries with preferencea
Budesonide/formoterol 20% 6 (Denmark, Finland, Germany, Norway, Spain, Sweden)
Fluticasone/formoterol 15% 2 (Italy, UK)
Fluticasone/salmeterol 10%
Ciclesonide/indacaterol 10%
Budesonide/salmeterol 9% 1 (Austria)
Ciclesonide/formoterol 7% 1 (Netherlands)
Beclometasone/formoterol 6%
Mometasone/indacaterol 5%
Mometosone/formoterol 3%
Other 15%
a More than one combination was equally preferred in Belgium, France and Switzerland.
formoterol (24%) and beclometasone/formoterol (20%). The
most common reasons given for treatment choice were
rapid onset of action (60%), high potency of ICS (39%),
efﬁcacy (15%) and experience of prescribing (13%).9
The second survey (performed in May and June 2010)
was developed in order to obtain a wider view of the
real-world attitudes and perceptions of physicians across
Europe.10 The survey formed part of a European Delphi
initiative (discussed in more detail below), which was
recently reported by Bousquet and colleagues, on behalf
of the Global Allergy and Asthma European Network.11 The
research set out to determine which molecules practising
physicians preferred and, furthermore, the attributes that
they considered to be most important when selecting an
ICS/LABA combination. The survey used computer-assisted
web interviews to collect information from over 1000
specialists and primary care physicians from 13 European
countries (Austria, Belgium, Denmark, Finland, France,
Germany, Italy, the Netherlands, Norway, Spain, Sweden,
Switzerland and the UK).
In rank order, the survey results demonstrated physician
preference (at least 10% of physicians) for: budesonide/
formoterol, ﬂuticasone/formoterol, ﬂuticasone/salmeterol
and ciclesonide/indacaterol (Table 1) (unpublished data).
Respondents rated the improvement in patient symptoms,
the potency of anti-inﬂammatory effect and improvement
in measures of lung function as the most important factors
when choosing a single-inhaler combination; rapid onset
of action, sustained duration of action, a ﬂexible dosing
approach, and the safety and tolerability of the ICS and LABA
were also among the attributes considered important.11
In terms of the LABA component (given alone or in
combination with an ICS for the maintenance treatment
of asthma), formoterol (65% overall) was clearly preferred
over salmeterol (33%); among the main reasons given for
selecting formoterol were a rapid onset of action, long-
acting effect and clinical effectiveness. Budesonide (52%)
and ﬂuticasone (25%) were the preferred ICSs (given alone
or in combination with a LABA inhaler), with respondents
from Sweden and Denmark showing a strong preference for
budesonide. The leading reasons for selection of budesonide
included experience/familiarity with the drug (77% of
physicians choosing the drug), effectiveness (61%), ﬂexible
dosing (40%) and trial evidence (34%). The main reasons
for selecting ﬂuticasone were clinical effectiveness (75%),
experience/familiarity (73%), trial evidence (53%) and long-
lasting action (40%). There was also a suggestion that cost
may have been an important factor inﬂuencing ICS selection
in countries where budesonide was the preferred ICS
(unpublished data).
Expert perspective: how do experts
recommend that physicians choose an
ICS/LABA combination?
The attitudes of specialists and primary care physicians
responsible for the routine care of patients with asthma
can usefully be compared with the views of experts in the
ﬁeld, as demonstrated in the recent article by Bousquet and
colleagues.11 A Delphi process, sponsored by Mundipharma
International Limited, aimed to gain the expert perspective
on factors that should be considered when selecting an
ICS/LABA combination for a patient with asthma.
The Delphi process is a validated technique for reaching
agreement in complex areas where evidence is incom-
plete.12 Anonymity, iteration and controlled feedback
enable experts to reﬁne their views in the light of the
available evidence.12 It has been used successfully to
address clinically relevant issues in asthma and chronic
obstructive pulmonary disease.13 16 Under the auspices
of the Global Allergy and Asthma European Network, a
Delphi process was initiated with the aim of reaching
agreement on the most important criteria to consider
when selecting an ICS/LABA combination therapy. Nineteen
experts from seven countries (Finland, France, Germany,
Italy, Spain, Sweden and the UK) took part in the process.
Consensus (deﬁned a priori as 66% agreement) was
reached on the six factors considered most important when
choosing a combination therapy. The panel agreed that
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Figure 3. Results of a Delphi process (n = 9) identifying the most important considerations when selecting an inhaled
corticosteroid (ICS) and long-acting b2-agonist (LABA) for the treatment of patients with asthma.
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the availability of a range of doses, the long-term safety
and tolerability of both the ICS and LABA, the efﬁcacy of
the combination, the potency of the ICS and the speed
of onset of the LABA (Fig. 3) were the most important
considerations.11
Conclusions
Several recent studies have shed light on the factors
underlying physician prescribing decisions about ICS/LABA
combination therapies. From an expert perspective, being
able to adjust the dose to optimize efﬁcacy (in terms
of improvements in symptoms and lung function) while
minimizing side effects is extremely important, with the
speed of onset of bronchodilation and potency of anti-
inﬂammatory effect being additional priorities. These views
are also borne out in surveys of the wider community
of respiratory physicians treating patients with asthma,
with clinical experience also playing a role. Given the
absence of clear guidance on the selection of a particular
ICS/LABA combination, it remains important to gain further
understanding of how physicians make such important
decisions in clinical practice. Further research is needed to
understand how physicians balance different factors when
choosing which ICS/LABA combination to prescribe to an
individual patient with asthma.
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